Merck has announced the signing of a memorandum of understanding with Kenya Medical Research Institution (KEMRI) for a scientific partnership aimed at contributing to the countryâ€™s social and economic development. The partnership will cover research and development projects, programs and activities focused on malaria and schistosomiasis, as well as related co-infections.
â€œKEMRI is especially delighted to partner with a company that is committed to building healthcare capacities and providing sustainable access to high-quality, safe medication and health solutions in developing countries,â€ said Solomon Mpoke, KEMRI Director and Chief Executive Officer.
Merck is planning to partner with other research institutes in Africa in order to deliver innovative products quickly and cost-effectively. The company aims to further develop research and development activities through its newly launched Translational Innovation Platform unit dedicated to deliver unique, integrated and affordable solutions to tackle unmet medical needs of major tropical diseases such as schistosomiasis and malaria affecting children in endemic countries.
The Merck Capacity Advancement Program (CAP) is a 5-year program aimed at expanding the professional capacity in Africa in the areas of research and development, clinical research, supply chain integrity and efficiency, pharmacovigilance, community awareness and education for medical students at African Universities.
Merck is committed to continue its efforts to fight schistosomiasis until the disease has been eliminated in Africa. Merckâ€™s efforts to fight schistosomiasis are in line with the United Nations Millennium Development Goals, and are also part of the initiative to fight neglected tropical diseases that was launched by the Bill & Melinda Gates Foundation in early 2012.